FDA Updates Approval History for Lucamzi (ranibizumab-blrz), a Biosimilar for Eye Conditions

The FDA's approval history for Lucamzi (ranibizumab-blrz), a biosimilar to Lucentis, was updated on October 31, 2026. Lucamzi is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). The approval was supported by a comprehensive comparative analytical assessment and a Phase 3 clinical study demonstrating equivalent efficacy and comparable safety to the reference product.